Skip to main content
Print Save

Generic Vonjo Availability

Last updated on Nov 7, 2023.

Vonjo is a brand name of pacritinib, approved by the FDA in the following formulation(s):

VONJO (pacritinib citrate - capsule;oral)

  • Manufacturer: CTI BIOPHARMA CORP
    Approval date: February 28, 2022
    Strength(s): EQ 100MG BASE [RLD]

Has a generic version of Vonjo been approved?

No. There is currently no therapeutically equivalent version of Vonjo available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vonjo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Oxygen linked pyrimidine derivatives
    Patent 8,153,632
    Issued: April 10, 2012
    Inventor(s): Blanchard Stephanie & Lee Cheng Hsia Angeline & Nagaraj Harish Kumar Mysore & Poulsen Anders & Sun Eric T. & Tan Yee Ling Evelyn & William Anthony Deodaunia
    Assignee(s): S*BIO Pte Ltd.

    The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumors and cancers as well as other disorders or conditions related to or associated with kinases.

    Patent expiration dates:

    • January 17, 2029
      ✓ 
      Patent use: USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • January 17, 2029
      ✓ 
      Patent use: TREATMENT OF MYELOFIBROSIS WITH PACRITINIB
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
    Patent 8,980,873
    Issued: March 17, 2015
    Inventor(s): Dymock Brian & Lee Cheng H. & William Anthony D.
    Assignee(s): CTI Biopharma Corp.

    The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions.

    Patent expiration dates:

    • March 25, 2030
      ✓ 
      Patent use: TREATMENT OF MYELOFIBROSIS WITH PACRITINIB
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • March 25, 2030
      ✓ 
      Patent use: USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Oxygen linked pyrimidine derivatives
    Patent 9,573,964
    Issued: February 21, 2017
    Inventor(s): Blanchard Stephanie & Lee Cheng Hsia Angeline & Nagaraj Harish Kumar Mysore & Poulsen Anders & Sun Eric T. & Tan Yee Ling Evelyn & William Anthony Deodaunia
    Assignee(s): CTI BIOPHARMA CORP.

    The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumors and cancers as well as other disorders or conditions related to or associated with kinases.

    Patent expiration dates:

    • May 5, 2028
      ✓ 
      Patent use: USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)
    • May 5, 2028
      ✓ 
      Patent use: TREATMENT OF MYELOFIBROSIS WITH PACRITINIB

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • February 28, 2027 - NEW CHEMICAL ENTITY
    • February 28, 2029 - TREATMENT OF ADULTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF) WITH A PLATELET COUNT BELOW 50 X 10^9/L

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer